Global Coronary Artery Disease Market – Industry Trends and Forecast to 2030

Global Coronary Artery Disease Market, By Diagnosis (Electrocardiogram, Echocardiogram, Stress Test, Cardiac catheterization, Heart CT Scan, Others) Treatment (Medication, Surgery, Additional Therapy, Others), End Users (Hospitals, Specialty Clinics, Others), and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) - Industry Trends and Forecast to 2030.

 Coronary Artery Disease Market Analysis and Size

Coronary artery disease refers to the market for diagnosing, treating, and managing the condition characterized by the narrowing or blockage of coronary arteries, which can lead to heart attacks and other cardiovascular complications.

Data Bridge Market Research analyses that the coronary artery disease market was valued at USD 22,943.21 million in 2022 and is expected to reach the value of USD 40,987.32 million by the year 2030, at a CAGR of 8.86% during the forecast period of 2023 to 2030. “Electrocardiogram” dominates the diagnosis segment of the coronary artery disease market owing to the increasing prevalence of Coronary artery disease globally. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Coronary Artery Disease Market Scope and Segmentation

Market Definition

Coronary artery disease is a progressive cardiovascular disease, in which the major blood vessels that supply the heart with blood, oxygen and nutrients (coronary arteries) become damaged or diseased. The damage in the arteries occurs due to the deposition of cholesterol (plaque) in arteries and inflammation is usually to blame for coronary artery disease. When plaque or blockage builds up, it narrows down the coronary arteries, decreasing blood flow in the heart. Ultimately, the decreased blood flow may cause chest pain (angina), shortness of breath, or other coronary artery disease signs and symptoms.

Global Coronary Artery Disease Market Dynamics

Drivers

• Rising Prevalence of Coronary Artery Disease (CAD)

Unhealthy lifestyles, such as sedentary behavior, poor diet, and smoking, coupled with aging populations, contribute to the increasing prevalence of CAD globally. This drives the demand for CAD diagnosis, treatment, and management.

• Advancements in Diagnostic Technologies

Technological advancements, such as non-invasive imaging techniques (e.g., CT angiography), molecular diagnostics, and high-sensitivity cardiac biomarkers, enable early and accurate diagnosis of CAD. These innovations enhance patient care and drive market growth.

• Increasing Adoption of Minimally Invasive Procedures

Minimally invasive procedures, such as percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), offer less invasive alternatives to traditional surgeries, reducing patient recovery time and improving outcomes.  

Opportunity

• Government Support and Innovation and Development

The government initiatives, schemes, or funding that support and promotes the innovation and development of the global coronary artery disease market provide growth opportunities for the market players in the forecast period of 2023 to 2030. In addition, development of innovative diagnostic tools and treatments, increasing research and development activities, penetration rate, market expansion in developing countries, integration of artificial intelligence and machine learning methods globally and increasing per capita expenditure on health care will further expand the market's growth rate in the future. 

Restraints/Challenges

• High Cost of Treatment and Procedures

The cost associated with CAD treatments, including medications, interventions, and surgeries, can be significant. Affordability and insurance coverage issues can limit access to quality care and pose challenges in managing CAD effectively.

• Early and Accurate Diagnosis

Early detection of CAD remains a challenge, as symptoms can be subtle or absent until advanced stages. The development of reliable and accessible diagnostic tools for early-stage CAD detection is crucial for effective disease management. Also, risk stratification and patient management among healthcare providers in the developing economies, adherence to lifestyle modifications and medications, and lack of suitable infrastructure in low-income and middle-income countries are projected to challenge the market in the forecast period of 2023-2030.

This coronary artery disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Coronary artery disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In April, 2021, According to Medscape Approximately 14 million Americans have CAD. Each year, 1.5 million individuals develop acute myocardial infarction (AMI), the most deadly presentation of CAD, and more than 500,000 of these individuals die

Global Coronary Artery Disease Market Scope

The global coronary artery disease treatment market is segmented on the basis of diagnosis, treatment, end users and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnosis

• Electrocardiogram
• Echocardiogram
• Stress Test
• Cardiac catheterization
• Heart CT Scan
• Others

Treatment

• Medication
• Beta-Blockers
• ACE Inhibitors
• Aldosterone Inhibitors
• Diuretics
• Vasodilators
• Others
• Surgery
• Balloon Angioplasty
• Coronary Artery Bypass Graft Surgery
• Enhanced External Counter Pulsation
• Others
• Additional Therapy
• Others

End Users

• Hospitals
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Coronary Artery Disease Market Regional Analysis/Insights

The global coronary artery disease market is analysed and market size insights and trends are provided by country, diagnosis, treatment, end-users and distribution channel as referenced above.

The countries covered in the global coronary artery disease market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E., Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA)

North America dominates the global coronary artery disease market due to the increased R&D activities in the industry and higher healthcare expenditure in this region.   

Asia-Pacific is expected to witness significant growth in the global coronary artery disease market during the forecast period of 2022 to 2029 due to huge patient population, coronary artery disease market and rise in the presence of huge opportunity in the market in this region

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The global coronary artery disease market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for coronary artery disease market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the coronary artery disease market. The data is available for historic period 2015-2020.

Competitive Landscape and Global Coronary Artery Disease Market Share Analysis

The global coronary artery disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Coronary artery disease market.

Some of the major players operating in the global coronary artery disease market are:

• Pfizer Inc. (U.S.)
• Amgen Inc. (U.S.)
• Cytokinetics (U.S.)
• Hikma Pharmaceutical PLC. (U.K.)
• AbbVie Inc. (U.S.)
• Lupin  (India)
• Wockhardt (India)
• GLENMARK PHARMACEUTICAL LTD. (India)
• Zydus Pharmaceutical Inc. (India)
• Amneal Pharmaceuticals LLC. (U.S.)
• Accord Healthcare (U.K.)
• Aurobindo Pharma (India)
• LG Chem. (South Korea)